(Q49032607)

English

Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram

scientific article published on September 22, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/20859636

Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram (English)

1 reference

10.1007/S00406-010-0149-3

https://api.crossref.org/works/10.1007/S00406-010-0149-3

17 July 2024

major depressive disorder

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Klaus Larsen

2

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/20859636

George I. Papakostas

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20859636

17 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20859636

17 July 2024

publication date

22 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/20859636

full work available at URL

http://link.springer.com/content/pdf/10.1007/s00406-010-0149-3.pdf

Portable Document Format

1 reference

10.1007/S00406-010-0149-3

https://api.crossref.org/works/10.1007/S00406-010-0149-3

17 July 2024

http://link.springer.com/article/10.1007/s00406-010-0149-3/fulltext.html

1 reference

10.1007/S00406-010-0149-3

https://api.crossref.org/works/10.1007/S00406-010-0149-3

17 July 2024

http://link.springer.com/content/pdf/10.1007/s00406-010-0149-3

1 reference

10.1007/S00406-010-0149-3

https://api.crossref.org/works/10.1007/S00406-010-0149-3

17 July 2024

European Archives of Psychiatry and Clinical Neuroscience

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/20859636

261

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/20859636

3

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/20859636

147-156

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/20859636

https://scigraph.springernature.com/pub.10.1007/s00406-010-0149-3

0 references

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Placebo response in studies of major depression: variable, substantial, and growing

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Mediators and moderators of treatment effects in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Major depressive subtypes and treatment response.

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study.

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the Treatment of Major Depressive Disorder With High Levels of Anxiety (Anxious Depression)

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Escitalopram in the acute treatment of depressed patients aged 60 years or older

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D.

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0149-3

21 January 2018

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20859636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20859636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20859636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20859636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escitalopram in the treatment of major depressive disorder: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20859636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20859636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escitalopram continuation treatment prevents relapse of depressive episodes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20859636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00406-010-0149-3

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/20859636

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/20859636

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49032607&oldid=2206854297"